Insulin human biosimilar(Ningbo Kunpeng Biotech)

Primary objective: To compare the pharmacokinetic similarity of human insulin injection developed by Ningbo Kunpeng Biotechnology Co., Ltd. and Humulin® single-dose subcutaneous injection in healthy male subjects using the euglycemic clamp technique; To compare the pharmacodynamic similarity of human insulin injection developed by Ningbo Kunpeng Biotechnology Co., Ltd. and Humulin® single-dose subcutaneous injection in healthy male subjects using the euglycemic clamp technique. Secondary objective: To evaluate the safety of human insulin injection in healthy male subjects.